Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jul 3, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that further clinical results from the Company's studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the New England Section of the American Urological ...Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH
...ently, hesitancy, weak stream, and other problems. More information about nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. Th...ities and Exchange Commission and other regulatory authorities. Contact nymox Pharmaceutical Corporation Roy Wolvin, 1-800-93NYMOX ...Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
...ently, hesitancy, weak stream, and other problems. More information about nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. Th...ities and Exchange Commission and other regulatory authorities. Contact nymox Pharmaceutical Corporation Roy Wolvin, 1-800-93NYMOXNymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
... HASBROUCK HEIGHTS, NJ (June 21, 2007) nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that detailed res...ently, hesitancy, weak stream, and other problems. More information about nymox is available at www.nymox.c...